Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review

OBJECTIVES: To examine the accessibility and quality of drug company payment data in Europe. DESIGN: Comparative policy review of payment data in countries with different regulatory approaches to disclosure. SETTING: 37 European countries. PARTICIPANTS: European Federation of Pharmaceutical Industri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozieranski, Piotr, Martinon, Luc, Jachiet, Pierre-Alain, Mulinari, Shai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679071/
https://www.ncbi.nlm.nih.gov/pubmed/34916317
http://dx.doi.org/10.1136/bmjopen-2021-053138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679071/
https://www.ncbi.nlm.nih.gov/pubmed/34916317
http://dx.doi.org/10.1136/bmjopen-2021-053138

Ejemplares similares